Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · August 09, 2016

All-Cause Mortality Reduction Associated WIth Use of PDE5 Inhibitor in Type 2 Diabetes

Heart (British Cardiac Society)

 

Additional Info

Heart (British Cardiac Society)
Phosphodiesterase Type-5 Inhibitor Use in Type 2 Diabetes Is Associated With a Reduction in All-Cause Mortality
Heart 2016 Jul 26;[EPub Ahead of Print], SG Anderson, DC Hutchings, M Woodward, K Rahimi, MK Rutter, M Kirby, G Hackett, AW Trafford, AH Heald

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading